These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 20167848

  • 21. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [Abstract] [Full Text] [Related]

  • 22. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
    Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T.
    Clin Cancer Res; 2005 Feb 01; 11(3):1312-8. PubMed ID: 15709203
    [Abstract] [Full Text] [Related]

  • 23. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 24. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G.
    Clin Cancer Res; 2005 Nov 01; 11(21):7891-900. PubMed ID: 16278414
    [Abstract] [Full Text] [Related]

  • 25. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD.
    Clin Cancer Res; 2005 Aug 01; 11(15):5515-25. PubMed ID: 16061868
    [Abstract] [Full Text] [Related]

  • 26. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T, Kamigaki T, Nakamura T, Imanishi T, Hayashi S, Kawasaki K, Takase S, Ajiki T, Kuroda Y.
    Oncol Rep; 2006 Dec 01; 16(6):1317-24. PubMed ID: 17089056
    [Abstract] [Full Text] [Related]

  • 27. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.
    Clin Cancer Res; 2018 Feb 15; 24(4):766-776. PubMed ID: 29233904
    [Abstract] [Full Text] [Related]

  • 28. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 29. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.
    Clin Cancer Res; 2005 Jul 15; 11(14):5292-9. PubMed ID: 16033848
    [Abstract] [Full Text] [Related]

  • 30. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
    Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D.
    Klin Padiatr; 2004 Jul 15; 216(3):176-82. PubMed ID: 15175963
    [Abstract] [Full Text] [Related]

  • 31. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH.
    Clin Cancer Res; 2003 Apr 15; 9(4):1517-27. PubMed ID: 12684428
    [Abstract] [Full Text] [Related]

  • 32. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 Apr 15; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

  • 33. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ.
    Cancer Res; 2001 Dec 01; 61(23):8513-9. PubMed ID: 11731436
    [Abstract] [Full Text] [Related]

  • 34. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S.
    Anticancer Res; 2013 Jul 01; 33(7):2971-6. PubMed ID: 23780988
    [Abstract] [Full Text] [Related]

  • 35. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
    Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH, Thurnher M.
    Clin Cancer Res; 2002 Nov 01; 8(11):3369-76. PubMed ID: 12429623
    [Abstract] [Full Text] [Related]

  • 36. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG.
    BJU Int; 2004 Aug 01; 94(3):412-8. PubMed ID: 15291878
    [Abstract] [Full Text] [Related]

  • 37. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, Nakamura M, Sugiyama H, Yonemitsu Y, Okamoto M, Hongo K.
    J Neurosurg; 2015 Oct 01; 123(4):989-97. PubMed ID: 26252465
    [Abstract] [Full Text] [Related]

  • 38. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M, Ebstein F.
    Bull Cancer; 2007 Jan 01; 94(1):23-31. PubMed ID: 17237002
    [Abstract] [Full Text] [Related]

  • 39. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, Mason MD, Tabi Z.
    Lung Cancer; 2012 Aug 01; 77(2):312-8. PubMed ID: 22498111
    [Abstract] [Full Text] [Related]

  • 40. [Dendritic cell therapy].
    Takahashi T.
    Nihon Rinsho; 2001 Dec 01; 59(12):2421-6. PubMed ID: 11766350
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.